-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OthtqBWjwTBnC4Cc+B+/Puc1mkYsjy4gxFv9ZE6LPMQTQHE2gL0NuRbMy+Pi4HV2 7rzCkQy12ofktLaTf5c2uA== 0001144204-07-069674.txt : 20071231 0001144204-07-069674.hdr.sgml : 20071231 20071231062457 ACCESSION NUMBER: 0001144204-07-069674 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20071220 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20071231 DATE AS OF CHANGE: 20071231 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUANTRX BIOMEDICAL CORP CENTRAL INDEX KEY: 0000820608 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330202574 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17119 FILM NUMBER: 071333197 BUSINESS ADDRESS: STREET 1: 100 SOUTH MAIN STREET STREET 2: SUITE 300 CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 267-880-1595 MAIL ADDRESS: STREET 1: 100 SOUTH MAIN STREET STREET 2: SUITE 300 CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: AFEM MEDICAL CORP DATE OF NAME CHANGE: 19970722 FORMER COMPANY: FORMER CONFORMED NAME: XTRAMEDICS INC /NV/ DATE OF NAME CHANGE: 19920703 8-K 1 v098401_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): December 20, 2007
 

QuantRx Biomedical Corporation
(Exact name of Registrant as Specified in Charter)

Nevada
 
0-17119
 
33-0202574
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

100 S. Main Street, Suite 300
Doylestown, Pennsylvania
 
 
18901
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (267) 880-1595

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 1.02  Termination of a Material Definitive Agreement
 
On December 20, 2007, QuantRx Biomedical Corporation, a Nevada corporation, delivered notice to Synova Healthcare, Inc., a Delaware corporation, terminating, effective immediately, the distribution agreement, dated as of July 7, 2006, by and among QuantRx Biomedical and Synova Healthcare, pursuant to which Synova Healthcare acted as the exclusive distributor of specified hemorrhoid products of QuantRx in the United States. The distribution agreement also granted Synova Healthcare a right of first offer and a right of first refusal with respect to all future line extensions and products or components related to the products that are covered by such agreement. Upon execution of the distribution agreement, Synova Healthcare paid to QuantRx Biomedical a non-refundable engagement fee.
 
QuantRx terminated the distribution agreement pursuant to Section 9.2 thereof and incurred no early-termination penalties as a result of such termination.
 
QuantRx filed a Current Report on Form 8-K regarding the execution of the distribution agreement with the Securities and Exchange Commission on July 13, 2006.
 
 
 
 

SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
  QUANTRX BIOMEDICAL CORPORATION
 
 		  
 		  
 
Date: December 31, 2007 By:   /s/ Walter Witoshkin
 
Walter Witoshkin
  Chairman and Chief Executive Officer
 
 
 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----